Nanobiotix: Advancing Pipeline, Strengthened Financing, and Extended Cash Horizon
Nanobiotix announces progress in its JNJ-1900 (NBTXR3) clinical program and presents its 2025 financial results in a press release dated March 31, 2026. The French biotech company aims to target several solid tumor indications through its two priority development pathways in head and neck cancer and lung cancer.
Progress in Clinical Development
The global development program for JNJ-1900 (NBTXR3) has progressed according to established plans, according to Nanobiotix. Two studies are the most advanced: the NANORAY-312 study in head and neck cancer, which saw the transfer of responsibility to Johnson & Johnson (Janssen) completed in the fourth quarter of 2025, and the CONVERGE study in lung cancer, where the first patient was treated in the first quarter of 2025 and initial data were presented in the first quarter of 2026. Concurrently, clinical data were reported in several types of early-stage solid tumors: esophageal cancer, pancreatic cancer, melanoma, and head and neck cancer. Phase 1 and 2 studies conducted by the MD Anderson Cancer Center (University of Texas) provided early tolerance and efficacy data. Additional presentations are expected in 2026 for studies in non-small cell lung cancer (NSCLC) with re-irradiation, pancreatic cancer, melanoma, and esophageal cancer.
Strengthened Financial Position
Nanobiotix has strengthened its financial position through a non-dilutive royalty sharing financing agreement signed with HealthCare Royalty that could reach up to 71 million US dollars, of which 50 million were received in December 2025. An amendment to the global licensing agreement with Janssen, executed in the first quarter of 2025, also removed the majority of the financial obligations related to the NANORAY-312 study. Based on the current operational plan, the cash position of 52.8 million euros as of December 31, 2025, will fund operations until the beginning of 2028, subject to the receipt of the remaining 21 million dollars from HealthCare Royalty.
Development of Curadigm Nanoprimer Platform
Nanobiotix continued the development of its Curadigm nanoprimer platform, its next-generation technology. Four new patent applications were filed in the fourth quarter of 2025. Preclinical in vivo data were presented evaluating the nanoprimer in combination with therapeutic vaccines. Chemistry, Manufacturing and Controls (CMC) activities were initiated to support the internal pipeline and external collaborations.
